A pharmaceutical study on certain transdermal delivery systems of an antiemetic drug /
Fouly, Aya Mohamed Adel Abdel Halim.
A pharmaceutical study on certain transdermal delivery systems of an antiemetic drug / دراسه صيدليه لانظمة توصيل عبر ا لجلد لعقار مضاد للقئ Aya Mohamed Adel AbdelHalim Fouly ; Supervisors Prof. Dr. Hussein Ammar (Professor, chairman of pharmaceutics and pharmaceutical technology department, faculty of pharmaceutical sciences and pharmaceutical industries, Future university in Egypt), Prof. Dr. Magdy Ibrahim (Professor of pharmaceutics and industrial pharmacy, faculty of pharmacy, Cairo university), Prof. Dr. Mina Ibrahim Tadros (Professor of pharmaceutics and industrial pharmacy, vice dean for community services and environment development affairs, faculty of pharmacy, Cairo university) - xi, 251 pages, 7 pages : illustrations (some color) ; 24 cm
Supervisors Prof. Dr. Hussein Ammar (Professor, chairman of pharmaceutics and pharmaceutical technology department, faculty of pharmaceutical sciences and pharmaceutical industries, Future university in Egypt), Prof. Dr. Magdy Ibrahim (Professor of pharmaceutics and industrial pharmacy, faculty of pharmacy, Cairo university), Prof. Dr. Mina Ibrahim Tadros (Professor of pharmaceutics and industrial pharmacy, vice dean for community services and environment development affairs, faculty of pharmacy, Cairo university)
Thesis (Ph.D.)-Cairo university, Faculty of pharmacy, Department of Pharmaceutics and Industrial pharmacy, 2018.
Includes bibliographical references.
Cancer treatment is commonly followed by nausea and emesis, namely: Chemotherapy-induced nausea and vomiting (CINV) which may affect the quality of patient life and lead to discontinuance or decreasing the dose of chemotherapy. 5-HT3 receptor antagonists showed superiority over other drugs in the prohibition and curing of CINV, Ondansetron hydrochloride (OND) is a 5-HT3 receptor antagonists commonly used for management of emesis after operations, radiotherapy or even chemotherapy. The oral dose of ondansetron is 8 mg. It is available in number of dosage forms; intravenous or intramuscular injections, tablets, oral solution, orally disintegrating tablets and suppositories. Ondansetron suffers from rapid elimination (tuzi 3-5 h) and low bioavailability (about 60%) as a result of first-pass metabolism effect. Moreover, frequent dosing and invasive dosage forms of ondansetron decrease patient compliance, hence, comes the importance of developing a convenient OND delivery system. Therefore, transdermal delivery may represent a good tool to increase convenience to the patient. Moreover, physicochemical properties of ondansetron HCI (Mw: 365.15; logD (pH5.5): 0.19; logP: 2.07) increase chances for successful transdermal delivery. This work investigated two different approaches for enhancing the transdermal delivery of OND. The first approach was loading OND into bilosomal systems in comparison to niosomes and conducting in-vitro and ex- vivo permeation and confocal laser scanning microscopy (CLSM) studies for evaluation of the best achieved systems. The second one included high frequency ultrasound mediated permeation of OND-loaded bilosomal gel systems at the optimized conditions followed by CLSM studies, The best achieved bilosomal system, bilosomal gel system, and high frequency ultrasound conditions were evaluated for in-vivo histopthological and permeation studies in comparison to commercial OND solution (emerest 2mg/mL.)
Text in English, abstracts in English and Arabic.
Pharmaceutics.
615.19 / F.A.P
A pharmaceutical study on certain transdermal delivery systems of an antiemetic drug / دراسه صيدليه لانظمة توصيل عبر ا لجلد لعقار مضاد للقئ Aya Mohamed Adel AbdelHalim Fouly ; Supervisors Prof. Dr. Hussein Ammar (Professor, chairman of pharmaceutics and pharmaceutical technology department, faculty of pharmaceutical sciences and pharmaceutical industries, Future university in Egypt), Prof. Dr. Magdy Ibrahim (Professor of pharmaceutics and industrial pharmacy, faculty of pharmacy, Cairo university), Prof. Dr. Mina Ibrahim Tadros (Professor of pharmaceutics and industrial pharmacy, vice dean for community services and environment development affairs, faculty of pharmacy, Cairo university) - xi, 251 pages, 7 pages : illustrations (some color) ; 24 cm
Supervisors Prof. Dr. Hussein Ammar (Professor, chairman of pharmaceutics and pharmaceutical technology department, faculty of pharmaceutical sciences and pharmaceutical industries, Future university in Egypt), Prof. Dr. Magdy Ibrahim (Professor of pharmaceutics and industrial pharmacy, faculty of pharmacy, Cairo university), Prof. Dr. Mina Ibrahim Tadros (Professor of pharmaceutics and industrial pharmacy, vice dean for community services and environment development affairs, faculty of pharmacy, Cairo university)
Thesis (Ph.D.)-Cairo university, Faculty of pharmacy, Department of Pharmaceutics and Industrial pharmacy, 2018.
Includes bibliographical references.
Cancer treatment is commonly followed by nausea and emesis, namely: Chemotherapy-induced nausea and vomiting (CINV) which may affect the quality of patient life and lead to discontinuance or decreasing the dose of chemotherapy. 5-HT3 receptor antagonists showed superiority over other drugs in the prohibition and curing of CINV, Ondansetron hydrochloride (OND) is a 5-HT3 receptor antagonists commonly used for management of emesis after operations, radiotherapy or even chemotherapy. The oral dose of ondansetron is 8 mg. It is available in number of dosage forms; intravenous or intramuscular injections, tablets, oral solution, orally disintegrating tablets and suppositories. Ondansetron suffers from rapid elimination (tuzi 3-5 h) and low bioavailability (about 60%) as a result of first-pass metabolism effect. Moreover, frequent dosing and invasive dosage forms of ondansetron decrease patient compliance, hence, comes the importance of developing a convenient OND delivery system. Therefore, transdermal delivery may represent a good tool to increase convenience to the patient. Moreover, physicochemical properties of ondansetron HCI (Mw: 365.15; logD (pH5.5): 0.19; logP: 2.07) increase chances for successful transdermal delivery. This work investigated two different approaches for enhancing the transdermal delivery of OND. The first approach was loading OND into bilosomal systems in comparison to niosomes and conducting in-vitro and ex- vivo permeation and confocal laser scanning microscopy (CLSM) studies for evaluation of the best achieved systems. The second one included high frequency ultrasound mediated permeation of OND-loaded bilosomal gel systems at the optimized conditions followed by CLSM studies, The best achieved bilosomal system, bilosomal gel system, and high frequency ultrasound conditions were evaluated for in-vivo histopthological and permeation studies in comparison to commercial OND solution (emerest 2mg/mL.)
Text in English, abstracts in English and Arabic.
Pharmaceutics.
615.19 / F.A.P